ABATTIS BIOCEUTICA COM NPV (OTCMKTS:ATTBF) Reaches Key Agreement

651

It has been quite a while since we last mentioned ABATTIS BIOCEUTICA COM NPV (OTCMKTS:ATTBF) here on Street Register, which at the time was just beginning to discuss pursuing a proprietary cannabis extraction technology using.

 

In chemistry, column chromatography is a method used to purify individual chemical compounds from mixtures of compounds. It’s just such technology that has allowed the company to form a newly announced agreement for cannabis-infused beverages, through a partnership the company has with EMERALD HEATH THE (OTCMKTS:EMHTF).

 

ABATTIS BIOCEUTICA COM NPV (OTCMKTS:ATTBF) announced the formation of a new partnership with Faculty Brewing Co, a Vancouver-based craft brewery, to develop a hemp-infused, cannabinoid-rich, THC-free craft beer. Pursuant to a research services agreement between Abattis and Faculty Brewing, Abattis will conduct research and development activities related to the development of a hemp-infused, cannabinoid-rich, THC-free craft beer, or a line of such beers, for Faculty Brewing.

 

“Our exciting partnership with Faculty Brewing positions us as one of the first Canadian companies to secure an agreement for research and development, analytical and regulatory services relating to a hemp- and cannabis-infused beverage,” said Rob Abenante, President and CEO of Abattis. “By aiming to develop a line of functional beers, each based on a different type of hemp extract, we hope to have a product that is compliant and market-ready as soon as Health Canada releases its new regulatory framework for hemp and cannabis-infused beverages,” added Mr. Abenante.

 

Northern Vine Laboratories has been contracted by Abattis to provide cannabinoid-rich, THC-free, hemp extract and to carry out research, development and analytical testing related to the formulation of a unique hemp- and cannabis-infused beer. Northern Vine is a Licensed Dealer under the provisions of the Canadian Controlled Drugs and Substances Act. As a Licensed Dealer, Northern Vine has the ability to import/export cannabis and cannabis oils, as well as the right to conduct certain activities related to the manipulation, formulation, dosage form, and strength or package size of cannabis, including mixtures with other additives, controlled substances, and non-controlled substances. Northern Vine is co-owned by Abattis and Emerald Health Therapeutics, which is a controlling shareholder.

 

“Having the Northern Vine team on board ensures the final product will deliver a precise and consistent amount of pesticide-free cannabinoids in every single bottle,” said Dr. David Galvez, Senior Science Advisor for Northern Vine and Abattis. (Source: Globe Newswire)

 

That news came just on the heels of another announcement, in which the company entered into a definitive agreement to acquire Green Tree Therapeutics Corporation. Green Tree Therapeutics brands are currently sold in a wide variety of brick and mortar locations across North America, including wholesale channels. The Green Tree acquisition will bring Abattis 10 unique branded SKUs and a series of marketing, licensing, and technology rights. Upon closing of the Acquisition, products within the Green Tree brand will made available through Abattis’s wholly-owned subsidiary Vergence Naturals Ltd. Moving forward within Abattis, Green Tree will continue to be engaged in expanding its product offerings for alternate cannabis products, including capsules, and lotions.

 

The Canadian Cannabis scene is only going to grow larger and more vibrant over the course of the next 6-12 months, which is why we want to keep a handle on just as many companies as we can. We’ve had ATTBF on our radars for a while and will continue to do so into the foreseeable future. Keep it locked on Street Register for updates, and we’ll deliver important developments on ATTBF as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!

 

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in ATTBF stock, short or long.

LEAVE A REPLY